Exendin 3 (9-39)

Exendin 3 (9-39) is a synthetic peptide fragment derived from the exendin-3 sequence, specifically lacking the first eight amino acids. As a truncated analog of exendin peptides, it is renowned for its ability to function as a competitive antagonist at the glucagon-like peptide-1 (GLP-1) receptor. This property has made it a valuable research tool in metabolic, endocrinological, and receptor pharmacology studies, where precise modulation of GLP-1 signaling is required. Its structural features and high specificity for GLP-1 receptors support a wide range of investigative applications in peptide biology and receptor-ligand interaction research.

Receptor antagonist studies: Exendin 3 (9-39) is extensively employed to probe the physiological and cellular effects mediated by GLP-1 receptor activation. By competitively inhibiting endogenous or exogenous GLP-1 agonists, it enables researchers to delineate the direct consequences of GLP-1 receptor blockade in various cell types and tissues. This approach is essential for dissecting the specific contributions of GLP-1 signaling in metabolic regulation, hormone secretion, and related pathways.

Signal transduction analysis: The peptide serves as a precise tool for mapping downstream signaling cascades initiated by GLP-1 receptor engagement. By selectively inhibiting receptor activation, investigators can measure changes in intracellular second messengers, such as cyclic AMP, and assess alterations in kinase activity or gene expression profiles. This facilitates a detailed understanding of the molecular mechanisms underlying GLP-1-dependent processes and supports the development of models for receptor-mediated signal transduction.

Metabolic research: In studies focused on glucose homeostasis, insulin secretion, and energy balance, exendin 3 (9-39) provides a robust means of evaluating the physiological relevance of GLP-1 signaling. Its antagonistic action allows for controlled experimentation on pancreatic islet function, hepatic glucose production, and peripheral glucose uptake. Researchers leverage this peptide to elucidate the interplay between incretin hormones and metabolic pathways, contributing to foundational knowledge in diabetes and obesity research.

Pharmacological profiling: The use of exendin 3 (9-39) in pharmacological assays enables detailed characterization of novel GLP-1 receptor ligands, including their potency, efficacy, and receptor selectivity. By serving as a reference antagonist, it assists in distinguishing specific GLP-1 receptor-mediated responses from off-target effects in both in vitro and ex vivo systems. This is particularly valuable for drug discovery efforts and structure-activity relationship studies involving incretin mimetics or related peptides.

Peptide-receptor interaction studies: Beyond its functional applications, exendin 3 (9-39) is instrumental in structural and biophysical investigations of peptide-receptor interactions. Its well-defined sequence and receptor specificity make it suitable for binding assays, affinity measurements, and studies employing techniques such as surface plasmon resonance or isothermal titration calorimetry. These approaches provide quantitative insights into the molecular determinants of GLP-1 receptor recognition and antagonism, advancing both basic and applied peptide science.

1. A possible role of tachykinin-related peptide on an immune system activity of mealworm beetle, Tenebrio molitor L

2. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

3. Myotropic activity and immunolocalization of selected neuropeptides of the burying beetle Nicrophorus vespilloides (Coleoptera: Silphidae)

4. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma

5. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate